-

01:22:46 PM

TNGX Stock News

TNGX - Tango Therapeutics Inc

09/18/23 7:00 AM

Nasdaq : TNGX

clinical trial

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that five abstracts have been selected for poster presentations at

RHEA-AI

neutral

09/06/23 7:00 AM

Nasdaq : TNGX

clinical trial

Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ Cancers

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the U.S. Food and Drug Administration (FDA) has cleared the

RHEA-AI

neutral

09/05/23 7:00 AM

Nasdaq : TNGX

conferences

Tango Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of

RHEA-AI

neutral

08/29/23 5:08 PM

Nasdaq : TNGX

management

Tango Therapeutics Announces Updates to Its Board of Directors

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced changes to its Board of Directors. John Ketchum has been appointed

RHEA-AI

neutral

08/10/23 7:00 AM

Nasdaq : TNGX

Tango Therapeutics Announces $80 million Private Placement Financing

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, has agreed to sell approximately 15.5 million shares of its common stock (“Common

RHEA-AI

neutral

08/07/23 7:00 AM

Nasdaq : TNGX

earnings

Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Highlights

– First patient dosed in phase 1/2 trial of TNG462, a next-generation PRMT5 inhibitor for the treatment of MTAP-deleted tumors – – Dose escalation ongoing in phase 1/2 trial of TNG908, a novel brain-penetrant PRMT5 inhibitor for the treatment of MTAP-deleted tumors – –First patient dosed in phase

RHEA-AI

neutral

07/24/23 7:00 AM

Nasdaq : TNGX

clinical trial

Tango Therapeutics Announces First Patient Dosed in TNG260 Phase 1/2 Trial in Patients With STK11-Mutant Cancers

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the phase 1/2 trial

RHEA-AI

neutral

07/10/23 7:00 AM

Nasdaq : TNGX

clinical trial

Tango Therapeutics Announces First Patient Dosed in TNG462 Phase 1/2 Trial in Patients With MTAP-deleted Solid Tumors

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the phase 1/2 trial of TNG462 in patients

RHEA-AI

neutral

06/01/23 7:00 AM

Nasdaq : TNGX

conferences

Tango Therapeutics to Participate in Upcoming Investor Conferences

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that members of the management team are scheduled to participate in

RHEA-AI

neutral

05/09/23 7:00 AM

Nasdaq : TNGX

earnings

Tango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights

– Dose escalation update from ongoing TNG908 clinical trial confirms proof-of-mechanism for MTA-cooperative tumor-selective PRMT5 inhibition in MTAP-deleted cancers – – FDA clears IND application for TNG260, a first-in-class CoREST complex inhibitor for the treatment of STK11-mutant cancers – –

RHEA-AI

neutral

TNGX Data

IndustryResearch and Development in Biotechnology
Websitetangotx.com
Security nameTango Therapeutics Inc
SectorProfessional, Scientific, and Technical Services

About Tango Therapeutics Inc

tango therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. tango was launched in 2017 with a $55 million series a investment from third rock ventures. the company has established a robust product engine that leverages advances in dna sequencing and crispr-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents. tango therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. these include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. what fuels each of tango’s programs is an increasingly sophisticated ability to util